Confirming the Stage: Diagnostic Tests and Estimates
At a Glance
Alcohol-associated cirrhosis is confirmed by combining a detailed alcohol history, tests that rule out other liver diseases, imaging, and blood work. FibroScan estimates liver stiffness, while platelet counts and other labs help assess severity and portal hypertension.
To effectively manage alcohol-associated cirrhosis, doctors must first confirm the diagnosis and then “stage” the disease to understand its severity. This process has moved away from invasive surgeries and toward non-invasive tests that use sound waves and blood markers to see inside the liver [1][2].
Confirming the Diagnosis
Diagnosing alcohol-associated cirrhosis is a process of “ruling in” the effects of alcohol while “ruling out” other potential causes of liver damage. Your medical team will typically look for three things:
- Alcohol History: A detailed history of alcohol exposure is required. Risk varies widely based on sex, genetics, body weight, metabolic disease, and drinking patterns. There is no single “daily drink cutoff” that definitively establishes or rules out the disease [3]. Doctors may use the AUDIT-C questionnaire or blood markers like Phosphatidylethanol (PEth) to objectively show recent alcohol exposure, though this does not prove alcohol caused the scarring on its own [4][5].
- Ruling Out Other Causes: Cirrhosis can also be caused by viral hepatitis (B or C), metabolic issues (fatty liver from diet/diabetes), medication toxicity, or autoimmune conditions [6][7]. Clinicians must actively evaluate these because it is common for alcohol to “interact” with metabolic factors, making the damage worse [6].
- Imaging and Labs: An ultrasound is often the first step to look for a “nodular” (lumpy) liver or an enlarged spleen (splenomegaly), which are signs of advanced disease [1][8].
Measuring Liver Stiffness (FibroScan)
A key part of staging is measuring liver stiffness. This is usually done with a FibroScan (transient elastography), which sends a pulse of sound through the liver. The faster the pulse travels, the stiffer—and more scarred—the liver is [1][2].
- LSM (Liver Stiffness Measurement): This is measured in kilopascals (kPa).
- Context matters: Cutoffs for liver stiffness are not universal rules you can apply yourself. Stiffness is heavily affected by active alcohol-associated hepatitis, cholestasis, congestion, recent food intake, obesity, and overall test quality [9][10]. A FibroScan cannot, by itself, establish the diagnosis or exact stage; it is an estimate interpreted by your clinician [11].
Evaluating Portal Hypertension (Baveno VII)
One of the most dangerous side effects of cirrhosis is portal hypertension, which is high pressure in the vein that enters the liver. This pressure can cause veins in the esophagus to swell (varices).
The Baveno VII guidelines allow doctors to use your FibroScan score and platelet count to decide if you need an endoscopy (a camera down the throat) to check for these swollen veins [12][11].
Can You Avoid an Endoscopy?
- Clinician-Interpreted Estimates: For appropriate, compensated patients, an endoscopy might be safely avoided if liver stiffness (LSM) is less than 20 kPa AND the platelet count is greater than 150,000/µL [11][13].
- Not a Rule for Everyone: This criteria applies to ruling out varices needing treatment. It should not be used by someone with a history of decompensation (like ascites or bleeding) to skip an endoscopy. Conversely, a stiffness over 25 kPa is a context-specific rule-in for clinically significant portal hypertension, but requires professional interpretation [12][9].
Lab Values to Track
When reviewing your pathology and lab reports, remember that clinicians combine these results with your symptoms and validated severity scores; they do not interpret one result in isolation. Keep a close eye on these specific markers:
- Platelets: A dropping platelet count is often a sign that portal hypertension is worsening, as the spleen begins to “trap” platelets when pressure rises, though it can fall for other reasons [14].
- AST/ALT Ratio: While an AST level more than twice the ALT level is suggestive of alcohol-related liver injury, it is neither necessary nor specific enough to confirm alcohol as the sole cause [1].
- Albumin: This is a protein made by the liver. A low albumin level suggests the liver’s “factory” is slowing down, but can also reflect malnutrition, inflammation, or kidney/intestinal issues [15].
- Kidney Function and Electrolytes: Track your creatinine, sodium, and potassium. The kidneys are intimately linked to liver health.
- Bilirubin and INR: INR measures selected clotting-factor activity (though not a complete measure of bleeding risk), and bilirubin measures waste clearance. Trends over time are vital [16][15].
Common questions in this guide
What tests are used to diagnose alcohol-associated cirrhosis?
What does a FibroScan measure in cirrhosis?
Can a FibroScan alone confirm the stage of cirrhosis?
When might someone with cirrhosis avoid an endoscopy?
Which blood tests are important when staging alcohol-associated cirrhosis?
Does an AST higher than ALT prove alcohol caused my cirrhosis?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my specific clinical history and lab results, how confident are we in the diagnosis of alcohol-associated cirrhosis?
- 2.How does my current liver stiffness (kPa) and platelet count influence your recommendation for or against an endoscopy right now?
- 3.Are there other potential causes of liver disease, such as viral hepatitis or metabolic issues, that you have ruled out?
- 4.What specific trends in my creatinine, sodium, and albumin should we be watching most closely?
- 5.Given my current level of disease compensation, how frequently should we be repeating these lab tests and non-invasive scans?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
Non-invasive diagnosis and biomarkers in alcohol-related liver disease.
Moreno C, Mueller S, Szabo G
Journal of hepatology 2019; (70(2)):273-283 doi:10.1016/j.jhep.2018.11.025.
PMID: 30658728 - 2
Prevalence and predictors of cirrhosis and portal hypertension in the United States.
Younossi ZM, de Avila L, Racila A, et al.
Hepatology (Baltimore, Md.) 2025; (82(5)):1229-1240 doi:10.1097/HEP.0000000000001243.
PMID: 39879587 - 3
Metabolic Dysfunction and Alcohol-Associated Liver Disease: A Narrative Review.
Dunn N, Al-Khouri N, Abdellatif I, Singal AK
Clinical and translational gastroenterology 2025; (16(5)):e00828 doi:10.14309/ctg.0000000000000828.
PMID: 39969015 - 4
Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?
Romero-Gómez M, Arab JP, Oliveira CP, et al.
Seminars in liver disease 2024; (44(1)):69-78 doi:10.1055/s-0044-1785228.
PMID: 38574752 - 5
Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications.
Díaz LA, Pose E, Israelsen M, Loomba R
Nature reviews. Gastroenterology & hepatology 2026; doi:10.1038/s41575-026-01240-6.
PMID: 42613422 - 6
A comprehensive review of diagnosis and management of alcohol-associated hepatitis.
Philips CA
SAGE open medicine 2024; (12()):20503121241297000 doi:10.1177/20503121241297000.
PMID: 39526098 - 7
Global burden of liver disease: 2023 update.
Devarbhavi H, Asrani SK, Arab JP, et al.
Journal of hepatology 2023; (79(2)):516-537 doi:10.1016/j.jhep.2023.03.017.
PMID: 36990226 - 8
Imaging of Alcohol-Associated Liver Disease.
Maheshwari S, Gu CN, Caserta MP, et al.
AJR. American journal of roentgenology 2024; (222(1)):e2329917 doi:10.2214/AJR.23.29917.
PMID: 37729554 - 9
Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial.
Dajti E, Villanueva C, Berzigotti A, et al.
Journal of hepatology 2025; (82(3)):490-498 doi:10.1016/j.jhep.2024.09.014.
PMID: 39303875 - 10
Validation of the New Diagnostic Criteria for Clinically Significant Portal Hypertension by Platelets and Elastography.
Podrug K, Trkulja V, Zelenika M, et al.
Digestive diseases and sciences 2022; (67(7)):3327-3332 doi:10.1007/s10620-021-07277-8.
PMID: 34739624 - 11
Non-invasive diagnosis and follow-up of portal hypertension.
Thabut D, Weil D, Bouzbib C, et al.
Clinics and research in hepatology and gastroenterology 2022; (46(8)):101767 doi:10.1016/j.clinre.2021.101767.
PMID: 34332128 - 12
Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis.
Dajti E, Ravaioli F, Zykus R, et al.
The lancet. Gastroenterology & hepatology 2023; (8(9)):816-828 doi:10.1016/S2468-1253(23)00150-4.
PMID: 37478880 - 13
Noninvasive assessment oesophageal varices: impact of the Baveno VI criteria.
Bai W, Abraldes JG
Current opinion in gastroenterology 2022; (38(3)):206-215 doi:10.1097/MOG.0000000000000824.
PMID: 35645017 - 14
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
Mandorfer M, Kozbial K, Freissmuth C, et al.
Alimentary pharmacology & therapeutics 2015; (42(6)):707-18 doi:10.1111/apt.13315.
PMID: 26179884 - 15
Predicting hepatic decompensation using non-invasive tests in a contemporary multicentre cohort of patients with cACLD.
Jachs M, Thöne P, Odriozola A, et al.
Journal of hepatology 2026; (84(4)):738-748 doi:10.1016/j.jhep.2025.10.019.
PMID: 41192692 - 16
Clinical relevance of shear wave elastography compared with transient elastography and other markers of liver fibrosis.
Ayonrinde OT, Zelesco M, Welman CJ, et al.
Internal medicine journal 2022; (52(4)):640-650 doi:10.1111/imj.15603.
PMID: 34726820
This page is for informational purposes only and does not constitute medical advice. Your healthcare team must interpret your alcohol-associated cirrhosis tests and decide which evaluations you need.
Get notified when new evidence is published on alcoholic liver cirrhosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.